As nations seek to stem the tide of rising health care spending, many have turned to cost-effectiveness research (CER) as a way to reduce spending on low-value interventions. Agencies in the United Kingdom, Italy, Germany, and Australia judge the clinical benefits and costs of new treatments relative to the current standards of care and set explicit thresholds to justify paying for new treatments.
In the United States, however, CER is the subject of ongoing political controversy, but little is known about Americans' attitudes toward government use of CER in decision making. In this article, we present findings from a recently conducted nationwide public survey about CER. We report public opinion on government use of CER and on specific decisions driven by CER using vignettes derived from real-world international decisions.
Methods | The data are derived from a survey by the Harvard School of Public Health. Institutional review board approval was waived. Field work was conducted using SSRS (Social Science Research Solutions; Media, Pennsylvania) via telephone (land line and cell) with a nationally representative sample of 1017 adults 18 years or older. To correct for nonresponse bias, responses were weighted according to US Census data to reflect the demographic makeup of the adult population. The margin of error is ±3.9 percentage points at the 95% confidence level.
The primary outcome measures for this study are support for a government CER agency and support for each of 4 CER-driven decision vignettes (see eAppendix 1 in the Supplement). Vignettes were written on the basis of decisions made by the Health Technology Assessment (HTA) bodies in 3 nations: the United Kingdom, Germany, and Italy. Vignettes were designed to present a fair depiction of how the debate over each decision was framed in each nation at the time to give as accurate a depiction as possible of how the debate might be framed in the United States for similar decisions. The intervention in question/disease/ country for the 4 decisions were as follows: (1) Avastin/ bowel cancer/United Kingdom, access to the drug limited to a subpopulation; (2) Avastin and/or Lucentis/wet agerelated macular degeneration (wet AMD)/Italy, reimbursement prov ided only for an off-label treatment; (3) β-interferon/multiple sclerosis/United Kingdom, drug not provided because life extension judged too short; and (4) positron emission tomography (PET) scans/head and neck tumors/Germany, imaging method allowed only for a subset of cancers. [1] [2] [3] [4] [5] [6] Results | Most of the overall study population opposed a government CER agency. About 56% of respondents would oppose such an agency (Table) . Democrats and Independents were about evenly split on the issue, while a significantly smaller percentage of Republicans would support such an agency (26.9%). Younger respondents, aged 18 to 29 years, were significantly more likely to support Supplemental content at jamainternalmedicine.com an agency (64.7%) than respondents 65 years or older (31.2%). None of the vignettes had majority support, with vignettes 1 and 2 holding significantly less support than a government CER agency. Unlike opinion over a government role for CER in coverage decisions, partisan affiliations do not appear to drive public opinion on specific vignette decisions.
Discussion | In the modern American political system, for a policy option to successfully navigate the path from a bill to a law often requires widespread public appeal, or at least little public opposition. This study should offer a warning to the research community that, despite the cost-saving potential of CER, it is likely to engender widespread opposition when put into practice in the United States-particularly if decisions are widely known by the public. Growing health care spending will require smarter choices on the part of health care payers and consumers. This research suggests that the public often will not support the federal government making those decisions for them. 
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Critical Access Hospitals and Cost Shifting
With more than 1300 acute care hospitals, the Critical Access Hospital (CAH) program is the largest Medicare program aimed at maintaining access to health care for rural Americans. 1 However, there is debate about how best to support the financial viability of CAHs while limiting rising health c are costs. Under Medicaid, almost 2 dozen states have adopted or are considering cost-based reimbursement for CAHs, while other states use alternative payment mechanisms.
2 President Barack Obama's 2014 budget proposal calls for a reduction in CAHs' Medicare reimbursement from 101% to 100% of costs. Several states have criticized the proposed cuts, 3 given the small margins of CAHs. 4 In the context of ongoing discussion about CAH reimbursement, it is important to better understand how health care providers currently utilize funds from the CAH Programs.
More than one-third of all CAHs are part of hospital systems that include non-CAH hospitals that are reimbursed prospectively (ie, with a prospectively set payment that is independent of the costs incurred). Prior research has shown that health care providers shift costs away from services reimbursed with a fixed amount and toward services reimbursed on a cost basis.
5 If systems strategically use accounting practices to shift costs to CAHs, eliminating such practices may offer one way to hold down health care costs while preserving the financial viability of CAHs.
Methods | Data are on the organizational level, and therefore institutional review board approval was not required. We used data obtained from the American Hospital Association Annual Survey to identify 94 systems with 302 hospitals that converted to CAH designation from 1997 to 2010, the period from the start of the CAH program to the most recent year for which cost data (from the Medicare Hospital Cost Reports) are available. Hospital systems frequently bundle services, such as information technology and management services, and provide them centrally at the parent organization. Medicare allows hospital systems to allocate these costs to system members; using a system member's share of inpatient days to allocate costs is consistent with Medicare guidelines. 6 The "administrative and general" cost category predominantly reflects costs from bundled services.
For each hospital system, we compared each system member's share of administrative and general costs to its share of total system inpatient days ( Table 1) . To capture the underlying accounting, we defined this as the allocation ratio. An allocation ratio of 1 indicates that a hospital's share of administrative and general costs follows its share of inpatient days.
We performed linear regression analysis on the sample to assess whether conversion to CAH designation (primary independent variable) was associated with a change in allocation ratio (primary dependent variable). Standard errors were clustered at the hospital system-year level. We defined statistical significance at the P < .05 level.
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